Please use this identifier to cite or link to this item: doi:10.22028/D291-39047
Title: Citraconate inhibits ACOD1 (IRG1) catalysis, reduces interferon responses and oxidative stress, and modulates inflammation and cell metabolism
Author(s): Chen, F.
Elgaher, W. A.M.
Winterhoff, M.
Büssow, K.
Waqas, F. H.
Graner, E.
Pires-Afonso, Y.
Casares Perez, L.
de la Vega, L.
Sahini, N.
Czichon, L.
Zobl, W.
Zillinger, T.
Shehata, M.
Pleschka, S.
Bähre, H.
Falk, C.
Michelucci, A.
Schuchardt, S.
Blankenfeldt, W.
Hirsch, A. K. H.
Pessler, F.
Language: English
Title: Nature Metabolism
Volume: 4
Issue: 5
Pages: 534-546
Publisher/Platform: Springer Nature
Year of Publication: 2022
Free key words: Applied immunology
Immunology
Metabolism
Metabolomics
DDC notations: 500 Science
Publikation type: Journal Article
Abstract: Although the immunomodulatory and cytoprotective properties of itaconate have been studied extensively, it is not known whether its naturally occurring isomers mesaconate and citraconate have similar properties. Here, we show that itaconate is partially converted to mesaconate intracellularly and that mesaconate accumulation in macrophage activation depends on prior itaconate synthesis. When added to human cells in supraphysiological concentrations, all three isomers reduce lactate levels, whereas itaconate is the strongest succinate dehydrogenase (SDH) inhibitor. In cells infected with influenza A virus (IAV), all three isomers profoundly alter amino acid metabolism, modulate cytokine/chemokine release and reduce interferon signalling, oxidative stress and the release of viral particles. Of the three isomers, citraconate is the strongest electrophile and nuclear factor-erythroid 2-related factor 2 (NRF2) agonist. Only citraconate inhibits catalysis of itaconate by cis-aconitate decarboxylase (ACOD1), probably by competitive binding to the substrate-binding site. These results reveal mesaconate and citraconate as immunomodulatory, anti-oxidative and antiviral compounds, and citraconate as the first naturally occurring ACOD1 inhibitor.
DOI of the first publication: 10.1038/s42255-022-00577-x
URL of the first publication: https://www.nature.com/articles/s42255-022-00577-x
Link to this record: urn:nbn:de:bsz:291--ds-390478
hdl:20.500.11880/35215
http://dx.doi.org/10.22028/D291-39047
ISSN: 2522-5812
Date of registration: 15-Feb-2023
Description of the related object: Supplementary information
Related object: https://static-content.springer.com/esm/art%3A10.1038%2Fs42255-022-00577-x/MediaObjects/42255_2022_577_MOESM1_ESM.pdf
https://static-content.springer.com/esm/art%3A10.1038%2Fs42255-022-00577-x/MediaObjects/42255_2022_577_MOESM2_ESM.pdf
https://static-content.springer.com/esm/art%3A10.1038%2Fs42255-022-00577-x/MediaObjects/42255_2022_577_MOESM3_ESM.xlsx
https://static-content.springer.com/esm/art%3A10.1038%2Fs42255-022-00577-x/MediaObjects/42255_2022_577_MOESM4_ESM.xlsx
https://static-content.springer.com/esm/art%3A10.1038%2Fs42255-022-00577-x/MediaObjects/42255_2022_577_MOESM5_ESM.pdf
Faculty: NT - Naturwissenschaftlich- Technische Fakultät
Department: NT - Pharmazie
Professorship: NT - Prof. Dr. Anna Hirsch
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
s42255-022-00577-x.pdf13,99 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons